Clinical trials: Semaglutide
Obesity & Overweight
WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults
This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug…
- Trial name
- NCT07216651
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Closed Loop Medicine
Overweight, Obesity
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo).
- Trial name
- OASIS 5 (NCT07770841)
- Testing
- Semaglutide
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 450 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM)
A Study of BGM0504 in Participants With Type 2 Diabetes
This trial is conducted in China. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin and/or sulfonylureas in patients with type 2 diabetes
- Trial name
- NCT06716216
- Testing
- Drug: 5 mg BGM0504 Administered SC, Drug:10 mg BGM0504 Administered SC, Drug: Semaglutide Administered SC
- Where
- China
- Volunteers
- 537 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obesity
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers.
- Trial name
- NCT05579249
- Testing
- Semaglutide, Orlistat, Phentermine/Topiramate
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects
The trial is conducted in Europe. The aim of the trial is to investigate the influence of semaglutide on the pharmacokinetics (the exposure of the trial drug in the body) of single doses of atorvastatin and digoxin in healthy…
- Trial name
- NCT02243098
- Testing
- semaglutide, digoxin, atorvastatin
- Where
- Germany
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61…
- Trial name
- ACHIEVE-3 (NCT06045221)
- Testing
- Orforglipron, Semaglutide
- Where
- 131 sites in United States, Argentina and 4 more
- Volunteers
- 1,698 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed to them by their doctor. The study will last for about 6 to 8 months.
- Trial name
- SURE SPAIN (NCT04067999)
- Testing
- Semaglutide
- Where
- 16 sites in Spain
- Volunteers
- 230 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema.
- Trial name
- REIMAGINE 5 (NCT06534411)
- Testing
- Cagrilintide, Semaglutide, Tirzepatide
- Where
- 163 sites in United States, Argentina and 12 more
- Volunteers
- 1,023 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects
This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), safety and…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02161588
- Testing
- semaglutide
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (mentioned as insulin glargine in this form) taken daily in people with type 2…
- Trial name
- COMBINE 4 (NCT06269107)
- Testing
- IcoSema, Insulin glargine
- Where
- 118 sites in United States, China and 8 more
- Volunteers
- 485 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
This study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and sitagliptin (a medicine doctors can already prescribe).
- Trial name
- PIONEER 12 (NCT04017832)
- Testing
- Oral semaglutide, Sitagliptin
- Where
- 93 sites in Algeria, Brazil and 7 more
- Volunteers
- 1,441 people
- Sponsor
- Novo Nordisk A/S
Obesity Control
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
This is a 48-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and WEGOVY® in patients with obesity.
- Trial name
- NCT07036172
- Testing
- HDM1702, Wegovy ®
- Where
- China
- Volunteers
- 460 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
- Trial name
- PIONEER 3 (NCT02607865)
- Testing
- semaglutide, sitagliptin
- Where
- 242 sites in United States, Argentina and 13 more
- Volunteers
- 1,864 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.
- Trial name
- SUSTAIN 7 (NCT02648204)
- Testing
- semaglutide, Dulaglutide
- Where
- 209 sites in United States, Bulgaria and 15 more
- Volunteers
- 1,201 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight, Mobility Disability
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
The primary objective of this study is to assess the effect of enobosarm on total body weight
- Conditions
- Obesity & Overweight, Mobility Disability, HOMA-IR
- Trial name
- PLATEAU (NCT07446998)
- Testing
- Enobosarm, Semaglutide (Wegovy) weekly injection
- Where
- 13 sites in United States
- Volunteers
- 239 people
- Sponsor
- Veru Inc.
Type 2 Diabetes
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite GLP-1-based therapy.
- Trial name
- NCT07502508
- Testing
- icovamenib 100 mg
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Biomea Fusion Inc.
Healthy Volunteers, Overweight
A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide
The study will look at how two different versions of semaglutide reach and stay in the blood after injection. The study aims to show similar levels of semaglutide in the blood when using the different versions.
- Conditions
- Healthy Volunteers, Overweight, Obesity
- Trial name
- NCT04228354
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India
The purpose of the study is to look at the change in blood sugar levels in participants with type 2 diabetes who start using oral semaglutide. Participants will get oral semaglutide as prescribed to them by the study doctor.
- Trial name
- PIONEER REAL (NCT05502562)
- Testing
- Oral semaglutide
- Volunteers
- 388 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to investigate the influence of omeprazole on the pharmacokinetics (the exposure of the trial drug in the body) of oral semaglutide in healthy subjects.
- Trial name
- NCT02249871
- Testing
- semaglutide, Omeprazole
- Where
- Germany
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity
Novo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants' body weight.
- Trial name
- OASIS 2 (NCT05132088)
- Testing
- semaglutide 50 mg
- Where
- 15 sites in Japan, South Korea
- Volunteers
- 201 people
- Sponsor
- Novo Nordisk A/S